Eisai is partnering with Wren Therapeutics to advance the discovery of new small molecule compounds capable of reducing the misfolding and aggregation of alpha-synuclein, the underlying cause of different neurological disorders, including Parkinson’s disease and dementia with Lewy bodies. The research collaboration will leverage Wren’s…
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Nuplazid (pimavanserin) that will allow the medication to be taken more easily by Parkinson’s patients who have difficulty swallowing. Nuplazid, by Acadia Pharmaceutical, is an oral medication that was approved…
AbFero Ltd will receive approximately €2 million ($2.41 million) through Eureka Network’s Eurostars program to complete pre-clinical testing of SP-420, a potential disease-modifying therapy for Parkinson’s disease, and to develop other iron-removing compounds. “This grant is an important step forward for AbFero as we test…
Xeomin (incobotulinumtoxinA) has been approved by Health Canada to treat adults with chronic sialorrhea — excessive drooling — a condition often experienced by people with neurological conditions like Parkinson’s disease. “The reality is that uncontrolled salivation is underestimated in many neurological diseases,” Michel…
Aggregates of alpha-synuclein alter the electrical activity of dopamine-producing neurons, demonstrating a mechanistic link between two key features of Parkinson’s disease, a new study reports. The findings also suggest that glibenclamide, a medication used to treat diabetes, can block these effects and, as such, may be useful…
The Michael J. Fox Foundation (MJFF) has honored three people with humanitarian and research awards for their work and commitment to movement disorders. Lily Safra, chairwoman of The Edmond J. Safra Philanthropic Foundation, was awarded the Edmond J. Safra Humanitarian Award. Researcher Caroline Tanner, MD, PhD, received…
The Michael J. Fox Foundation and the Shake It Up Australia Foundation are supporting an international project investigating the role of fatty molecules — called lipids — in the brains of people with Parkinson’s disease. “There is very little known about the role of changes in lipid metabolism…
Two nonprofits, Parkinson’s U.K. and The Michael J. Fox Foundation have partnered with Neurolixis to support a clinical trial testing the safety, tolerability, and early efficacy of NLX-112, the company’s candidate to ease  dyskinesia and the severity of some non-motor symptoms due to Parkinson’s disease. Data from…
A simple eye exam, coupled with artificial intelligence (AI) technology, could improve the diagnosis of neurodegenerative disorders, according to researchers at the University of Florida who have applied AI technologies to detect early signs of Parkinson’s disease. These research findings are being presented in a scientific poster, titled…
Levodopa, and especially levodopa/carbidopa intestinal gel (LCIG) — a formulation of levodopa and carbidopa infused directly into the intestines — can alter gut bacteria composition and metabolism, acting as drivers of bowel inflammation and possibly of disease progression in people with Parkinson’s disease, a study reported.
Get regular updates to your inbox.
